We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
323 result(s) found, displaying 71 to 80
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort Respules 500mcg/2ml.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort 0.25 mg/ml nebuliser suspension.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort 0.25mg/mL nebulizer suspension.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort 0.50mg/mL nebulizer suspension.
-
Designation or determinationProvisional determination
-
Australian public assessment report (AusPar)Imjudo (tremelimumab) is approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian public assessment report (AusPar)Imfinzi (Durvalumab) has been approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian public assessment report (AusPar)Andexxa (andexanet alfa) is provisionally approved for adult patients treated with a direct factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RILAST RAPIHALER budesonide / formoterol fumarate dihydrate 200/6 pressurised metered dose inhaler.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RILAST RAPIHALER budesonide / formoterol fumarate dihydrate 100/3 pressurised metered dose inhaler.